Niranjan Manoharan
Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 7 | 2026 | 211 | 3.290 |
Why?
| | Geographic Atrophy | 11 | 2026 | 105 | 1.970 |
Why?
| | Retinal Diseases | 2 | 2025 | 102 | 1.570 |
Why?
| | Macular Degeneration | 9 | 2026 | 196 | 1.420 |
Why?
| | Tomography, Optical Coherence | 13 | 2026 | 283 | 1.400 |
Why?
| | Retinal Detachment | 3 | 2022 | 74 | 1.390 |
Why?
| | Vitreoretinopathy, Proliferative | 2 | 2022 | 15 | 1.340 |
Why?
| | Fluorescein Angiography | 11 | 2026 | 197 | 1.280 |
Why?
| | Vitreous Body | 4 | 2022 | 118 | 1.020 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2025 | 37 | 0.910 |
Why?
| | Complement System Proteins | 4 | 2026 | 326 | 0.870 |
Why?
| | Diabetes Mellitus | 2 | 2024 | 1101 | 0.860 |
Why?
| | Visual Acuity | 13 | 2026 | 499 | 0.830 |
Why?
| | Macular Edema | 2 | 2026 | 49 | 0.820 |
Why?
| | Cataract | 2 | 2023 | 240 | 0.750 |
Why?
| | Insulins | 1 | 2023 | 39 | 0.750 |
Why?
| | Vitreous Detachment | 1 | 2022 | 6 | 0.750 |
Why?
| | Ophthalmology | 1 | 2023 | 122 | 0.700 |
Why?
| | Wet Macular Degeneration | 4 | 2026 | 63 | 0.690 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 983 | 0.570 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2623 | 0.570 |
Why?
| | Lens Implantation, Intraocular | 2 | 2018 | 80 | 0.550 |
Why?
| | Registries | 7 | 2025 | 2400 | 0.540 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 23 | 0.530 |
Why?
| | Glaucoma, Open-Angle | 1 | 2018 | 109 | 0.480 |
Why?
| | Phacoemulsification | 1 | 2018 | 124 | 0.480 |
Why?
| | Biomarkers | 8 | 2026 | 4340 | 0.440 |
Why?
| | Choroid | 2 | 2025 | 81 | 0.410 |
Why?
| | Antineoplastic Agents | 1 | 2025 | 2219 | 0.410 |
Why?
| | Multimodal Imaging | 2 | 2025 | 137 | 0.390 |
Why?
| | Vitrectomy | 3 | 2022 | 74 | 0.360 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2026 | 778 | 0.330 |
Why?
| | Epiretinal Membrane | 2 | 2020 | 7 | 0.320 |
Why?
| | Aged, 80 and over | 11 | 2026 | 8391 | 0.320 |
Why?
| | Retrospective Studies | 11 | 2025 | 17438 | 0.320 |
Why?
| | Retinal Perforations | 2 | 2020 | 18 | 0.320 |
Why?
| | Aged | 19 | 2026 | 26432 | 0.310 |
Why?
| | Follow-Up Studies | 12 | 2026 | 5439 | 0.300 |
Why?
| | Central Nervous System Neoplasms | 1 | 2012 | 177 | 0.290 |
Why?
| | Humans | 36 | 2026 | 146342 | 0.280 |
Why?
| | Uveitis, Anterior | 1 | 2026 | 27 | 0.230 |
Why?
| | Fovea Centralis | 1 | 2025 | 24 | 0.230 |
Why?
| | Middle Aged | 16 | 2026 | 36619 | 0.230 |
Why?
| | Optical Imaging | 1 | 2026 | 63 | 0.220 |
Why?
| | Complement Activation | 2 | 2025 | 412 | 0.220 |
Why?
| | Fundus Oculi | 4 | 2026 | 89 | 0.220 |
Why?
| | Ocular Hypertension | 1 | 2026 | 72 | 0.220 |
Why?
| | Risk Factors | 7 | 2025 | 10921 | 0.220 |
Why?
| | Male | 21 | 2026 | 73396 | 0.200 |
Why?
| | Retinal Drusen | 1 | 2024 | 31 | 0.200 |
Why?
| | India | 5 | 2024 | 213 | 0.200 |
Why?
| | Hospitals, County | 1 | 2023 | 11 | 0.200 |
Why?
| | Female | 22 | 2026 | 79499 | 0.200 |
Why?
| | Intraocular Pressure | 3 | 2026 | 344 | 0.190 |
Why?
| | Scleral Buckling | 1 | 2022 | 16 | 0.190 |
Why?
| | Retinal Vein Occlusion | 1 | 2022 | 14 | 0.180 |
Why?
| | Retinal Vein | 1 | 2022 | 14 | 0.180 |
Why?
| | Brain Neoplasms | 1 | 2012 | 1325 | 0.180 |
Why?
| | Cluster Analysis | 1 | 2023 | 496 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2024 | 545 | 0.170 |
Why?
| | Complement Factor B | 1 | 2022 | 106 | 0.170 |
Why?
| | Esophageal Neoplasms | 1 | 2025 | 351 | 0.170 |
Why?
| | Retinoschisis | 1 | 2020 | 2 | 0.160 |
Why?
| | Disease Progression | 5 | 2026 | 2867 | 0.160 |
Why?
| | Nanopores | 1 | 2020 | 13 | 0.160 |
Why?
| | Membranes, Artificial | 1 | 2020 | 67 | 0.150 |
Why?
| | Retina | 1 | 2022 | 330 | 0.150 |
Why?
| | Machine Learning | 1 | 2026 | 594 | 0.150 |
Why?
| | Neoplasms | 3 | 2024 | 2954 | 0.150 |
Why?
| | Nanotechnology | 1 | 2020 | 114 | 0.150 |
Why?
| | Internet | 1 | 2023 | 660 | 0.140 |
Why?
| | Eye Diseases, Hereditary | 1 | 2018 | 15 | 0.140 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.140 |
Why?
| | Axial Length, Eye | 1 | 2018 | 17 | 0.140 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.140 |
Why?
| | Adenocarcinoma | 1 | 2025 | 927 | 0.140 |
Why?
| | Pseudophakia | 1 | 2018 | 21 | 0.140 |
Why?
| | Refraction, Ocular | 1 | 2018 | 47 | 0.130 |
Why?
| | Medicare | 1 | 2024 | 920 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 846 | 0.130 |
Why?
| | Trabeculectomy | 1 | 2018 | 76 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2024 | 947 | 0.120 |
Why?
| | Adult | 8 | 2025 | 41087 | 0.120 |
Why?
| | Lenses, Intraocular | 1 | 1996 | 49 | 0.120 |
Why?
| | Cross-Sectional Studies | 5 | 2025 | 5899 | 0.110 |
Why?
| | Incidence | 4 | 2024 | 2936 | 0.110 |
Why?
| | Retinal Pigment Epithelium | 2 | 2024 | 81 | 0.100 |
Why?
| | Tobacco Smoke Pollution | 1 | 2016 | 227 | 0.100 |
Why?
| | Glaucoma | 1 | 1996 | 267 | 0.090 |
Why?
| | Metabolomics | 1 | 2018 | 738 | 0.090 |
Why?
| | ras GTPase-Activating Proteins | 1 | 2012 | 16 | 0.090 |
Why?
| | Lymphocyte Subsets | 1 | 2012 | 79 | 0.090 |
Why?
| | Intracellular Space | 1 | 2012 | 64 | 0.090 |
Why?
| | Protein Multimerization | 1 | 2012 | 201 | 0.080 |
Why?
| | Cell Communication | 1 | 2012 | 327 | 0.080 |
Why?
| | Young Adult | 2 | 2019 | 14330 | 0.070 |
Why?
| | Smoking | 1 | 2016 | 1486 | 0.070 |
Why?
| | Prospective Studies | 3 | 2026 | 8123 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2026 | 3017 | 0.070 |
Why?
| | Surveys and Questionnaires | 3 | 2026 | 6073 | 0.070 |
Why?
| | Algorithms | 2 | 2026 | 1849 | 0.070 |
Why?
| | Adolescent | 2 | 2019 | 22557 | 0.060 |
Why?
| | Sickness Impact Profile | 1 | 2026 | 67 | 0.060 |
Why?
| | Prognosis | 3 | 2024 | 4351 | 0.060 |
Why?
| | United States | 1 | 2024 | 16136 | 0.060 |
Why?
| | Intravitreal Injections | 1 | 2026 | 73 | 0.060 |
Why?
| | Cataract Extraction | 2 | 1998 | 120 | 0.060 |
Why?
| | Uncertainty | 1 | 2026 | 145 | 0.050 |
Why?
| | Antibodies, Bispecific | 1 | 2026 | 70 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2026 | 239 | 0.050 |
Why?
| | Age Factors | 1 | 2012 | 3347 | 0.050 |
Why?
| | Time Factors | 2 | 2025 | 7109 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2026 | 295 | 0.050 |
Why?
| | Demography | 1 | 2024 | 274 | 0.050 |
Why?
| | Chemokine CCL5 | 1 | 2023 | 40 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2026 | 1331 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 207 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | HIV Infections | 1 | 2018 | 3215 | 0.040 |
Why?
| | Quality of Life | 2 | 2026 | 3200 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 182 | 0.040 |
Why?
| | Vision Disorders | 1 | 2022 | 179 | 0.040 |
Why?
| | Dialysis | 1 | 2020 | 18 | 0.040 |
Why?
| | Adsorption | 1 | 2020 | 154 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 244 | 0.040 |
Why?
| | Infant, Newborn | 1 | 2012 | 6460 | 0.040 |
Why?
| | Rabbits | 1 | 2020 | 651 | 0.040 |
Why?
| | Xanthine | 1 | 2018 | 7 | 0.030 |
Why?
| | Infant | 1 | 2012 | 10114 | 0.030 |
Why?
| | Purines | 1 | 2018 | 188 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 196 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1998 | 157 | 0.030 |
Why?
| | Child, Preschool | 1 | 2012 | 11913 | 0.030 |
Why?
| | Polymers | 1 | 2020 | 488 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 779 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2018 | 729 | 0.030 |
Why?
| | Colorado | 1 | 2025 | 4595 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 390 | 0.030 |
Why?
| | Postoperative Complications | 2 | 1998 | 3034 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2244 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3206 | 0.020 |
Why?
| | Glucose | 1 | 2018 | 1053 | 0.020 |
Why?
| | Population Surveillance | 1 | 2016 | 481 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2919 | 0.020 |
Why?
| | Child | 1 | 2012 | 22693 | 0.020 |
Why?
| | Protein Interaction Mapping | 1 | 2012 | 105 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2018 | 1369 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2861 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2012 | 3125 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2012 | 4118 | 0.010 |
Why?
| | Animals | 2 | 2020 | 38106 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5246 | 0.010 |
Why?
| | Eyeglasses | 1 | 1998 | 27 | 0.010 |
Why?
| | Safety | 1 | 1998 | 347 | 0.010 |
Why?
| | Mice | 1 | 2012 | 18297 | 0.010 |
Why?
| | Treatment Outcome | 1 | 1998 | 11821 | 0.000 |
Why?
|
|
Manoharan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|